China SXT Launches $12M Registered Direct Offering, Diluting Existing Holders
SXTC sits 37% above its 52-week low of $1.18 on elevated volume (38× avg).
Summary
China SXT Pharmaceuticals announced a $12 million registered direct offering with certain institutional investors, a 33% increase over the $9 million offering it completed in July 2026. The offering consists of 8,000,000 units at $1.50 per unit, each unit comprising one Class A ordinary share or pre-funded warrant and one warrant to purchase one Class A ordinary share. The warrants are immediately exercisable at $2.75 per share, have a one-year term, and include a zero cash exercise option to acquire up to 9 Class A shares per warrant, potentially adding up to 72,000,000 shares. Investors also have an additional purchase right for up to $12 million of securities for 30 days. The company has a market cap of only $3.7 million, so this raise is highly dilutive to existing shareholders. The offering comes just two months after the prior raise and follows a $3 million private placement that was signed and terminated within a day on October 7-8, 2026. The company also has an active $100 million at-the-market offering program, indicating ongoing capital needs. The stock trades at $1.62, and the offering price of $1.50 per unit suggests significant downward pressure on the share price. The offering is expected to close on or about October 9, 2026, with Univest Securities, LLC acting as sole placement agent, pursuant to a shelf registration statement on Form F-3 effective December 1, 2025.
Updated with an SEC 424B5 filing · What changed
Updates
· SEC 424B5 — The 424B5 prospectus finalizes the $12 million offering: 8,000,000 units at $1.50 each, with warrants exercisable at $2.75 and a zero-price exercise option that could add up to 72,000,000 shares.
· SEC 6-K — The warrants in the $12 million registered direct offering have an exercise price of $2.75 per share, correcting a typographical error in the initial press release.
- Offering Terms — The offering is with certain institutional investors, involving 8,000,000 Class A ordinary shares or pre-funded warrants at a purchase price of $1.50 per share, and the company will issue 8,000,000 warrants.
- Warrant Terms — Warrants are immediately exercisable upon issuance, have a 1-year term from the date of issuance, and each warrant has a zero cash exercise option to acquire up to 9 Class A shares.
- Additional Purchase Right — Investors have an additional purchase right for up to $12 million of securities for 30 days.
- Closing and Placement Agent — The offering is expected to close on or about October 9, 2026, with Univest Securities, LLC acting as the sole placement agent.
- Registration Statement — The offering is made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) effective December 1, 2025.
All 11 details
- The offering is with certain institutional investors.
- It involves 8,000,000 Class A ordinary shares or pre-funded warrants.
- The purchase price for the shares is $1.50 per share.
- The company will issue 8,000,000 warrants.
- Warrants are immediately exercisable upon issuance.
- Warrants have a 1-year term from the date of issuance.
- Each warrant has a zero cash exercise option to acquire up to 9 Class A shares.
- Investors have an additional purchase right for up to $12 million of securities for 30 days.
- The offering is expected to close on or about October 9, 2026.
- Univest Securities, LLC is acting as the sole placement agent.
- The offering is made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) effective December 1, 2025.
At the time of this announcement, SXTC was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.18 to $83,758.24. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.